Trading Signals: NVAX Stock Price Prediction and Forecast (Tue. Apr. 1, 2003 - Tue. Jan. 26, 2021)(Novavax, Inc.)
| NVAX latest price $155.8300 (8.84%) ($144.6940 - $159.9700) on Mon. Aug. 3, 2020. | |
| | Trend Analysis and Forecast | | | Trend Pattern | Growing Uptrend | Trend Narrative | Uptrend | Average Daily Price Swing | $22.03 (17.07% one month average) | Average Daily Percentage Swing | 11.25% (three month average) | Weekly Trend Force | 1.8% (StdDev 11.25%) | Daily Moving Force | 2.3% | Correction Force | Weak (0%) | Trend | 2.08% | Trend Strength | 11.7% | RSI | 79 | Momentum | 1.5 | Latest Price | $155.8300(8.84%) | Forecasted Low Price | 151.47(-2.8%) | Forecasted High Price | 166.58(6.9%) | Direction of Next Movement | Range(4.4%) | % Change Needed to Confirm Correction | 13.2% (137.68) | % Change Needed for Trend Reversal | 13.7% | Hourly Trend | 2.9% [$149.18(4.33), $147.76(2)] | Stocks Behave Similarly | Similar Stock List | Complacency | 7 | Intraday Reversal Probability | There's a high probability the price will reverse sharply to downside intraday or next day.. | Daily Trend | NVAX advances 2.3% a day on average for past five trading days. | Weekly Trend | NVAX advances 8.7% a week on average for past two weeks. | Market Behavior | Growth stock rally for large cap. Broad based rally for small cap. | Correlated ETFs | Broad market will support NVAX advance at 1.7% a week (29% probability) XBI(35%) ARKG(30%) IBB(29%) VCSH(27%) IPO(23%) | Factors Impacting NVAX price | NVAX will decline at least -1.4% in a week (7% probabilities). EDOC(-8%) UUP(-7%) IYT(-7%) TBT(-6%) XLC(-5%) | Explanation | The rally is not sustainable and not supported by the broad market. | Trading Plan | Not Available | | | Valuation to SPY | 1.3 | | | Relative Volatility | 0.7 (options are expensive) | | | Market Trend Strength | 2.1% (StdDev 11.25%) | Hourly BBV | 2.1 () | Intraday Trend | 0% | | | |
|
Next Day Open Price | $158.48(1.7%) | Support Level | $129.05 | 5 Day Moving Average | $147.89(5.37%) | 10 Day Moving Average | $144.18(8.08%) | 20 Day Moving Average | $129.05(20.75%) | To recent high | 0% | To recent low | 807.8% | Market Cap | $9.539b | | Option Sentiment | | | | Earning Release Date | Mon. Mar. 1, 2021 | Analyst One Year Target Price | $129.00 ($105.00 - $155.00) 5 analysts (last updated on Wed. Jul. 15, 2020) | % to Average Target Price | -17.22% | % to Low Target Price | -32.62% | % to High Target Price | -0.53% | | |
Novavax, Inc. is operates as a clinical-stage biotechnology company, which focuses on the discovery, development and commercialization of vaccines to prevent infectious diseases. It produces vaccine candidates to respond to both known and emerging disease threats by using the proprietary recombinant nanoparticle vaccine technology. The firm's vaccine candidates include ResVax and NanoFlu. It also develops immune stimulating saponin-based adjuvants through its wholly owned Swedish subsidiary, Novavax AB. The company was founded in 1987 and is headquartered in Gaithersburg, MD.
JUL 7, 2020 Shares of NVAX surged more than 40% on the news ts has received $1.6 to develop and to deliver up to 100 million doses of the company’s late-stage Covid-19 vaccine candidate as part of the U.S. government’s Operation Warp Speed program. The vaccine, which focuses on boosting the body’s immune system to effectively combat a Covid-19 infection, is currently in phase 1 and phase 2 clinical trials in Australia, with preliminary results expected at the end of this month. |